Financial insights of NXGL

MyFinsight

For the quarter ending 2026-03-31, NXGL made $2,650K in revenue. -$927K in net income. Net profit margin of -34.98%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenues, net	2,650	2,797	2,934	2,884
Cost of revenues	1,589	1,977	1,691	1,626
Gross margin	1,061	820	1,243	1,258
Research and development	-	-6	7	0
Selling, general and administrative	2,019	2,040	1,961	1,894
Total operating expenses	2,019	2,034	1,968	1,894
Loss from operations	-958	-1,214	-725	-636
Change in fair value of warrant liability, net of warrant modification expense	-	30*	-	-
Interest expense, net	-	9*	-	-
Gain on investments	-	-	-	0
Gain in spin-off of nexgelrx	-	41*	-	-
Interest income (expense), net	-42	-	10	-21
Other expense	6	-106*	-	37
Loss on sale of assets	-	-	-	0
Other income	135	118	59	41
Changes in fair value of warrant liability	-	-	9	13
Total other income (expense), net	87	286	78	-4
Loss before income taxes	-871	-928	-647	-640
Income tax expense	-	-	-	0
Net loss	-871	-928	-647	-640
Less income attributable to non-controlling interest in joint venture	56	42	6	25
Net loss attributable to nexgel stockholders	-927	-970	-653	-665

Basic EPS	-0.11	-0.119	-0.08	-0.09
Diluted EPS	-0.11	-0.119	-0.08	-0.09
Basic Average Shares	8,204,205	8,146,194	7,971,299	7,654,348
Diluted Average Shares	8,204,205	8,146,194	7,971,299	7,654,348

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.